Epidemiology
The CYP2C19*2 polymorphism, is also known as poor metabolizer because it has been related with a decreased enzymatic activity function, specially in those who have the presence of the SNP in both alleles, that strongly suggest a reduction in clopidogrel matabolism leading to a decrease in its antiplatelet effect. According to a study performed with 51 mexican patients, 9 (17%) of them were found to carry the CYP2C19*2 polymorphism. Of these, seven (13.7%) were heterozygotes and two (3.9%) were homozygous. The remaining 42 patients had the wild-type genotype. This results showed that 3.9% of patients had the homozygous genotype, wich is higher thant the previously reported frequency of 0-1.45% in the Mexican Mestizo groups.